Pharmacology of Restless Legs Syndrome (RLS)

<p>1. Adenosine mechanisms and hypersensitive corticostriatal terminals in restless legs syndrome. Rationale for the use of inhibitors of adenosine transport<br>Sergi Ferré, César Quiroz, William Rea, Xavier Guitart and Diego García-Borreguero<br>2. D3 receptor agonist efficacy in restless legs syndrome<br>Francesca Casoni, Andrea Galbiati and Luigi Ferini-Strambi<br>3. The heterotetrameric structure of the adenosine A1-dopamine D1 receptor complex: Pharmacological implication for restless legs syndrome<br>Antoni Cortés, Verònica Casadó-Anguera, Estefanía Moreno and Vicent Casadó<br>4. D3 and D1 receptors: The Yin and Yang in the treatment of restless legs syndrome with dopaminergics<br>Stefan Clemens and Imad Ghorayeb<br>5. The neurophysiology of hyperarousal in restless legs syndrome: Hints for a role of glutamate/GABA<br>Giuseppe Lanza and Raffale Ferri<br>6. Iron uptake at the blood-brain barrier is influenced by sex and genotype<br>Quinn W. Wade, Brian Chiou and James R. Connor<br>7. Caenorhabditis elegans and its applicability to studies on restless legs syndrome<br>Pan Chen, Omamuyovwi Meashack Ijomone, Kun He Lee and Michael Aschner<br>8. Role of MEIS1 in restless legs syndrome: From GWAS to functional studies in mice<br>Aaro V. Salminen, Daniel D. Lam and Juliane Winkelmann<br>9. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome<br>Vivian Wanner, Celia Garcia Malo, Sofía Romero, Irene Cano-Pumarega and Diego García-Borreguero<br>10. Idiopathic restless legs syndrome treatment: Progress and pitfalls?<br>Imad Ghorayeb<br>11. Treatment of pediatric restless legs syndrome<br>Lourdes DelRosso and Oliviero Bruni<br>12. Pharmacological treatments of augmentation in restless legs syndrome patients<br>Claudia Trenkwalder and Walter Paulus</p>